Anti-Monkeypox virus/MPXV A35R Nanobody (A145)
Référence APR11086
Conditionnement : 0.1mg
Marque : Abcepta
Anti-Monkeypox virus/MPXV A35R nanobody (A145)
Antibody
Anti-Monkeypox virus/MPXV A35R Nanobody (A145) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Application ![]()
| Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA |
|---|---|
| Clonality | Monoclonal |
| Isotype | VHH |
| Target/Specificity | A35R |
|---|---|
| Endotoxin | <0.001 EU/ µg |
| Conjugation | None |
| Expression system | CHO |
| Format | nanobody |
| Molecular Weight (kDa) | 78.24 kDa |
| Formulation | 0.1 mM Glycine, 0.2 Mm Nacl, (tris), pH 5 |
| Storage | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.
Research Areas
- Primary Antibodies
- Antibody Collections
- Recombinant Antibodies




